{"id":476384,"date":"2021-04-14T16:09:02","date_gmt":"2021-04-14T20:09:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/"},"modified":"2021-04-14T16:09:02","modified_gmt":"2021-04-14T20:09:02","slug":"biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/","title":{"rendered":"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">CAMBRIDGE, Mass., April  14, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lUERnD8hvf-mpzM4c3GHmt_GRQe6LbR-ghYCr2IIgxDRzG6ULmonKgfEfxhFYKGpGhiZiKbVpkfUmHVnk06xYQ==\" rel=\"nofollow noopener\" target=\"_blank\">Biogen<\/a> (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer\u2019s disease investigational therapy, aducanumab, at the upcoming 2021 virtual American Academy of Neurology (AAN) Annual Meeting.<\/p>\n<p>\n        <strong><br \/>\n          <em>AAN Poster Presentation Details:<\/em><br \/>\n        <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Saturday, April 17, 2021, 8:00 a.m. ET \u2013<em> EMBARK: A Phase 3b, open-label, single-arm, safety study to evaluate the long-term safety and efficacy of aducanumab in eligible participants with Alzheimer\u2019s disease<\/em><em>with Carmen Castrillo-Viguera, M.D., Senior Medical Director, Clinical Development at Biogen<\/em><\/li>\n<\/ul>\n<p>To access the poster presentation, please go to the Investors section of Biogen\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1uMoeq-VGUTvB4Y_VZuwSGbli9IzsTvj8YN5uTePPRnqmHNC5X1DMJol6gd_L90XAE7RLvaZu2_uBMs_RAlSx7hXJQEt8QvCo0NPr7tHyQU=\" rel=\"nofollow noopener\" target=\"_blank\">investors.biogen.com<\/a>. Following the event, an archived version will be available on the website.<\/p>\n<p>\n        <strong>About Biogen<\/strong><br \/>\n        <br \/>At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world\u2019s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer\u2019s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology and neuropathic pain.<\/p>\n<p>We routinely post information that may be important to investors on our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FRN7xz7M1bQyA9Sy_Z0Jx81V3vGHS-hYvZLPpRDND8WNcCYVczgIzB2MlTAs0HLDdaao3O3ht1aFHXssq-xR6A==\" rel=\"nofollow noopener\" target=\"_blank\">www.biogen.com<\/a>. To learn more, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FRN7xz7M1bQyA9Sy_Z0Jxwzboz4WWGbuGWb6Tws4wtpRtUSoJUmGrtEqQYgg79j2xLWKlul_TRREWUdifCDRqQ==\" rel=\"nofollow noopener\" target=\"_blank\">www.biogen.com<\/a> and follow us on social media \u2013 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hr714RrUfaHXPgJ3OB68ZllRV_D98iUvEiTxHQMKskqUtrIQGboIS5LC-CCuf7MdzLhc9mikKtNxDgH2c_tVCQ==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aWEm8UT1iHFxhbfKueFEPA40HSdk3noWT7kiJjRWLVSkIPfpGuqmr1_whqHMaexhcnavQooHtaImNfmVdaILCUHavuCb7bc29i5F0QD6540=\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FZRIRKwZC2lLGgLanno-dvvYY1P1CvJBee09TTyH3zeQwbycC95kbG-AZIXxaLGXmkTmbdR4d-VzkivXkHhYEA==\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EGmUfZpDouSbXLDQcP7xT-_ni8kY26n97LPcvnF385NNSqe6P7Qfr5stl4xGMR-GJghN1CgUds_AmUzfA8lTJA==\" rel=\"nofollow noopener\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p>\n        <strong>About Aducanumab<\/strong><br \/>\n        <br \/>Aducanumab (BIIB037) is an investigational human monoclonal antibody studied for the treatment of Alzheimer\u2019s disease. Based on clinical data from patients with Mild Cognitive Impairment due to Alzheimer\u2019s disease and mild Alzheimer\u2019s disease, aducanumab has the potential to impact underlying disease pathophysiology, slow cognitive and functional decline and provide benefits on patients\u2019 ability to perform activities of daily living, including conducting personal finances, performing household chores, such as cleaning, shopping and doing laundry, and independently traveling out of the home. If approved, aducanumab would be the first treatment to meaningfully change the course of the disease for individuals living with Alzheimer\u2019s.<\/p>\n<p>Biogen licensed aducanumab from Neurimmune under a collaborative development and license agreement. Since October 2017 Biogen and Eisai have collaborated on the development and commercialization of aducanumab globally.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: top\">MEDIA CONTACT:<\/p>\n<p>David Caouette \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>+1 617 679 4945<br \/><a href=\"mailto:public.affairs@biogen.com\" rel=\"nofollow noopener\" target=\"_blank\">public.affairs@biogen.com<\/a><\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: top\">INVESTOR CONTACT:<\/p>\n<p>Mike Hencke<br \/>+1 781 464 2442<br \/><a href=\"mailto:IR@biogen.com\" rel=\"nofollow noopener\" target=\"_blank\">IR@biogen.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzA1MSM0MTIxMjMwIzIwMDk2ODQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/aeb619c1-45e6-492b-b65a-2547863cc176\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) &#8212; Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer\u2019s disease investigational therapy, aducanumab, at the upcoming 2021 virtual American Academy of Neurology (AAN) Annual Meeting. AAN Poster Presentation Details: Saturday, April 17, 2021, 8:00 a.m. ET \u2013 EMBARK: A Phase 3b, open-label, single-arm, safety study to evaluate the long-term safety and efficacy of aducanumab in eligible participants with Alzheimer\u2019s diseasewith Carmen Castrillo-Viguera, M.D., Senior Medical Director, Clinical Development at Biogen To access the poster presentation, please go to the Investors section of Biogen\u2019s website at investors.biogen.com. Following the event, an archived version will be available on the website. About Biogen &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-476384","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) &#8212; Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer\u2019s disease investigational therapy, aducanumab, at the upcoming 2021 virtual American Academy of Neurology (AAN) Annual Meeting. AAN Poster Presentation Details: Saturday, April 17, 2021, 8:00 a.m. ET \u2013 EMBARK: A Phase 3b, open-label, single-arm, safety study to evaluate the long-term safety and efficacy of aducanumab in eligible participants with Alzheimer\u2019s diseasewith Carmen Castrillo-Viguera, M.D., Senior Medical Director, Clinical Development at Biogen To access the poster presentation, please go to the Investors section of Biogen\u2019s website at investors.biogen.com. Following the event, an archived version will be available on the website. About Biogen &hellip; Continue reading &quot;Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-14T20:09:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzA1MSM0MTIxMjMwIzIwMDk2ODQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021\",\"datePublished\":\"2021-04-14T20:09:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\\\/\"},\"wordCount\":445,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzA1MSM0MTIxMjMwIzIwMDk2ODQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\\\/\",\"name\":\"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzA1MSM0MTIxMjMwIzIwMDk2ODQ=\",\"datePublished\":\"2021-04-14T20:09:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzA1MSM0MTIxMjMwIzIwMDk2ODQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxNzA1MSM0MTIxMjMwIzIwMDk2ODQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/","og_locale":"en_US","og_type":"article","og_title":"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021 - Market Newsdesk","og_description":"CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) &#8212; Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer\u2019s disease investigational therapy, aducanumab, at the upcoming 2021 virtual American Academy of Neurology (AAN) Annual Meeting. AAN Poster Presentation Details: Saturday, April 17, 2021, 8:00 a.m. ET \u2013 EMBARK: A Phase 3b, open-label, single-arm, safety study to evaluate the long-term safety and efficacy of aducanumab in eligible participants with Alzheimer\u2019s diseasewith Carmen Castrillo-Viguera, M.D., Senior Medical Director, Clinical Development at Biogen To access the poster presentation, please go to the Investors section of Biogen\u2019s website at investors.biogen.com. Following the event, an archived version will be available on the website. About Biogen &hellip; Continue reading \"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-14T20:09:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzA1MSM0MTIxMjMwIzIwMDk2ODQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021","datePublished":"2021-04-14T20:09:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/"},"wordCount":445,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzA1MSM0MTIxMjMwIzIwMDk2ODQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/","name":"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzA1MSM0MTIxMjMwIzIwMDk2ODQ=","datePublished":"2021-04-14T20:09:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzA1MSM0MTIxMjMwIzIwMDk2ODQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxNzA1MSM0MTIxMjMwIzIwMDk2ODQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biogen-to-present-trial-design-of-aducanumab-embark-re-dosing-study-in-poster-session-at-2021-virtual-aan-annual-meeting-on-april-17-22-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Biogen to Present Trial Design of Aducanumab EMBARK Re-Dosing Study in Poster Session at 2021 Virtual AAN Annual Meeting on April 17-22, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476384","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=476384"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/476384\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=476384"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=476384"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=476384"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}